An Open-label, Randomized Phase 3 Efficacy Study of ASP8

Project: Research project

Project Details

Description

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations
StatusActive
Effective start/end date12/1/1512/31/20

Funding

  • ASTELLAS PHARMA, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.